Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

A.T. Shaw, T.M. Kim, L. Crinò, C. Gridelli, K. Kiura, G. Liu, S. Novello, A. Bearz, O. Gautschi, T. Mok, M. Nishio, G. Scagliotti, D.R. Spigel, S. Deudon, C. Zheng, S. Pantano, P. Urban, C. Massacesi, K. Viraswami-Appanna, E. Felip

Research output: Contribution to journalArticle

Cite this

Shaw, A. T., Kim, T. M., Crinò, L., Gridelli, C., Kiura, K., Liu, G., Novello, S., Bearz, A., Gautschi, O., Mok, T., Nishio, M., Scagliotti, G., Spigel, D. R., Deudon, S., Zheng, C., Pantano, S., Urban, P., Massacesi, C., Viraswami-Appanna, K., & Felip, E. (2017). Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 18(7), 874-886. https://doi.org/10.1016/S1470-2045(17)30339-X